Revance Therapeutics (RVNC) Misses Q2 EPS by 2c

Revance Therapeutics (NASDAQ: RVNC) reported Q2 EPS of ($1.07), $0.02 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $18 million versus the consensus estimate of $15.48 million.

Cash, cash equivalents and short-term investments as of June 30, 2021 were $336.3 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen